# A Study of Psilocybin for Major Depressive Disorder (MDD)

> **NCT03866174** · PHASE2 · COMPLETED · sponsor: **Usona Institute** · enrollment: 347 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Niacin
- **OTHER:** Set and Setting (SaS) Protocol

## Key facts

- **NCT ID:** NCT03866174
- **Lead sponsor:** Usona Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-23
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-06-28
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866174, "A Study of Psilocybin for Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03866174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*